Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| INCB024360 | INCB024360. Group: Biochemicals. Alternative Names: (E)-4-amino-N-(3-Chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide. Grades: Highly Purified. CAS No. 914471-09-3. Pack Sizes: 25mg. US Biological Life Sciences. |  Worldwide |
| INCB024360-analog | Potent competitive inhibitor of IDO1 with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model; This INCB024360-analog decreased kynurenine levels by >50% in plasma and inhibited B16-GM-CSF tumor growth in a dose dependent fashion. Synonyms: INCB-24360; INCB024360; INCB 024360; INCB-024360; indoleamine-2,3-dioxygenase inhibitor INCB024360. Grades: > 98%. CAS No. 914471-09-3. Molecular formula: C9H7ClFN5O2. Mole weight: 271.64. |  |
| INCB054329 | INCB054329 is a novel bromodomain and extraterminal domain (BET) inhibitor. It induces vulnerabilities in myeloma cells by inhibition of BET protein. Uses: Antineoplastic agents. Synonyms: INCB-054329; INCB-54329; 7-(3,5-Dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one. CAS No. 1628607-64-6. Molecular formula: C19H16N4O3. Mole weight: 348.36. | |
| INCB054329 | INCB054329 is a potent BET inhibitor. Uses: Scientific research. Group: Signaling pathways. CAS No. 1628607-64-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112504. |  |
| INCB057643 | INCB057643 is a bromodomain and extraterminal domain (BET) inhibitor. It binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. Synonyms: INCB-057643; 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-benzo[b][1,4]oxazin-3(4H)-one. CAS No. 1820889-23-3. Molecular formula: C20H21N3O5S. Mole weight: 415.46. | |
| INCB086550 | INCB086550 is A Potent and Novel Small-Molecule PD-L1 Inhibitor. In vitro, INCB086550 selectively and potently blocked the PD-L1/PD-1 interaction, induced PD-L1 dimerization and internalization, and induced stimulation-dependent cytokine production in primary human immune cells. In vivo, INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade. Preliminary data from an ongoing phase I study confirmed PD-L1/PD-1 blockade in peripheral blood cells, with increased immune activation and tumor growth control. Group: Inhibitors. Alternative Names: INCB086550; INCB-086550; INCB 086550; INCB86550; INCB-86550; INCB 86550; PD-1; PD-L1-IN-8. CAS No. 2230911-59-6. Molecular formula: C41H39N7O4. Mole weight: 693.81. Appearance: Solid powder. Purity: >98%. IUPACName: 1-((7-cyano-2-(3'-((3-((3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid. Canonical SMILES: CC1=C (C=CC=C1C2=NC3=CC (=CC (=C3O2)C#N)CN4CCC (C4)C (=O)O)C5=C (C (=CC=C5)NC6=NC=CC7=CC (=CN=C76)CN8CCC (C8)O)C. Catalog: ACM2230911596. |  |
| INCB086550 | INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC 50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: PD-1/PD-L1-IN-8. CAS No. 2230911-59-6. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-134884. | |
| INCB16562 | INCB16562 is a novel, selective, and orally bioavailable small-molecule inhibitor of JAK1 and JAK2 markedly selective over JAK3. Treatment of myeloma cells with INCB16562 potently inhibited interleukin-6 (IL-6)-induced phosphorylation of STAT3. INCB16562 abrogated the protective effects of recombinant cytokines or bone marrow stromal cells and sensitized myeloma cells to cell death by exposure to dexamethasone, melphalan, or bortezomib. Oral administration of INCB16562 antagonized the growth of myeloma xenografts in mice and enhanced the antitumor activity of relevant agents in combination studies. INCB16562 is a potent JAK1/2 inhibitor and that mitigation of JAK/STAT signaling by targeting JAK1 and JAK2 will be beneficial in the treatment of myeloma patients, particularly in combination with other agents. Synonyms: INCB-16562; INCB 16562; 2-(2,6-dichlorophenyl)-1,8-dihydroimidazo[4,5-d]dipyrido[2,3-b:4',3'-f]azepine. CAS No. 933768-63-9. Molecular formula: C19H11Cl2N5. Mole weight: 380.23. | |
| Incb18424 | Heterocyclic Organic Compound. CAS No. 1160597-27-2. Molecular formula: C17H18N6. Mole weight: 306.37. Catalog: ACM1160597272. | |
| INCB 3284 | INCB 3284 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 of 3.7 nM. Synonyms: N-(2-(((R)-1-((1r,4R)-4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)pyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide dimethanesulfonate; INCB3284; INCB 3284; INCB-3284; INCB3284 mesylate; INCB3284 dimesylate. CAS No. 887401-92-5. Molecular formula: C26H31F3N4O4. Mole weight: 520.54. | |
| INCB 3284 dimesylate | INCB 3284 dimesylate. Group: Biochemicals. Grades: Purified. CAS No. 887401-93-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| INCB 3284 dimesylate | INCB 3284 dimesylate is a potent, selective and orally bioavailable CCR2 antagonist with IC50 of 3.7 nM. Synonyms: INCB 3284 dimesylate; INCB3284 dimesylate; INCB-3284 dimesylate; N-[2-[[(3R)-1-[trans-4-hydroxy-4-(6-methoxy-3-pyridinyl)cyclohexyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-benzamide, dimethanesulfonate. CAS No. 887401-93-6. Molecular formula: C26H31F3N4O4.2CH4O3S. Mole weight: 712.76. | |
| INCB3344 | INCB3344 is a potent CCR2 antagonist with IC50 of 5.1 nM and 9.5 nM for hCCR2 and mCCR2, respectively. Synonyms: INCB3344; INCB 3344; INCB-3344; N-(2-(((3S,4S)-1-(4-(Benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide. CAS No. 1262238-11-8. Molecular formula: C29H34F3N3O6. Mole weight: 577.59. | |
| INCB-9471 Dihydrochloride | INCB-9471 HCl is an allosteric non-competitive small molecule antagonist of C-C chemokine receptor 5, which has strong inhibitory activity on monocyte migration and HIV-1 infection. Synonyms: Methanone,(4,6-Dimethyl-5-Pyrimidinyl)[4-[(3S)-4-[(1R,2R)-2-Ethoxy-2,3-Dihydro-5-(Trifluoromethyl)-1H-Inden-1-Yl]-3-Methyl-1-Piperazinyl]-4-Methyl-1-Piperidinyl]-,Hydrochloride (1:2). Grades: 98%. CAS No. 869725-27-9. Molecular formula: C30H42Cl2F3N5O2. Mole weight: 632.6. | |
| Aderbasib | Aderbasib is a azaspiro[2. 5]octanehydroxamide derivative as inhibitor of metalloproteases for the treatment of disorders such as cancer, arthritis, cardiovascular or skin disorders. Aderbasib, also known as INCB007839, is a sheddase inhibitor, is also an orally bioavailable inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity. Aderbasib represses the metalloproteinase "sheddase" activities of ADAM10 and ADAM17, which may result in the inhibition of tumor cell proliferation. The metalloproteinase domains of ADAMs cleave cell surface proteins at extracellular sites proximal to the cell membrane, releasing or "shedding" soluble protein etcodomains from the cell surface; the disintegrin domains of these multifunctional proteins interact with various components of the extracellular matrix (ECM). Group: Biochemicals. Alternative Names: (6S, 7S) -7-[ (Hydroxyamino) carbonyl]-6-[ (4-phenyl-1-piperazinyl) carbonyl]-5-azaspiro[2. 5]octane-5-carboxylic Acid Methyl Ester; INCB 007839. Grades: Highly Purified. CAS No. 791828-58-5. Pack Sizes: 1mg, 5mg. Molecular Formula: C??H??N?O?, Molecular Weight: 416.47. US Biological Life Sciences. | Worldwide |
| Aderbasib | Aderbasib is a sheddase inhibitor, is also an orally bioavailable inhibitor of the ADAM (A Disintegrin And Metalloprotease) family of multifunctional membrane-bound proteins with potential antineoplastic activity. Aderbasib represses the metalloproteinase "sheddase" activities of ADAM10 and ADAM17, which may result in the inhibition of tumor cell proliferation. Synonyms: INCB7839; INCB 7839; INCB-7839; INCB007839; INCB 007839; INCB-007839. CAS No. 791828-58-5. Molecular formula: C21H28N4O5. Mole weight: 416.48. | |
| Baricitinib | Baricitinib. Group: Biochemicals. Alternative Names: INCB 028050; LY 3009104; 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile. Grades: Highly Purified. CAS No. 1187594-09-7. Pack Sizes: 5mg. Molecular Formula: C16H17N7O2S, Molecular Weight: 371.42. US Biological Life Sciences. | Worldwide |
| Baricitinib | Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC 50 s of 5.9 nM and 5.7 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LY3009104; INCB028050. CAS No. 1187594-09-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-15315. | |
| Baricitinib phosphate | Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). Baricitinib has been approved by FDA for the treatment of rheumatoid arthritis (RA). Synonyms: INCB 028050; LY 3009104; INCB028050; LY3009104; LY-3009104; INCB-028050. Grades: >98%. CAS No. 1187595-84-1. Molecular formula: C16H20N7O6PS. Mole weight: 469.41. | |
| Baricitinib phosphate | Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable JAK1 / JAK2 inhibitor with IC 50 of 5.9 nM and 5.7 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LY3009104 phosphate; INCB028050 phosphate. CAS No. 1187595-84-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15315A. | |
| Capmatinib | Capmatinib, also known as INCB28060 and INC280, is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. It selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. It has been granted Breakthrough Therapy Designation by FDA as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC). Synonyms: INCB28060; INC-280; INC280. CAS No. 1029712-80-8. Molecular formula: C23H17FN6O. Mole weight: 412.43. | |
| Capmatinib | Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor ( IC 50 =0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INC280; INCB28060. CAS No. 1029712-80-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-13404. | |
| Capmatinib dihydrochloride hydrate | Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor ( IC 50 =0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INC280 dihydrochloride hydrate; INCB-28060 dihydrochloride hydrate. CAS No. 1865733-40-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13404C. | |
| Capmatinib hydrochloride | Capmatinib (INC280; INCB28060) hydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor ( IC 50 =0.13 nM). Capmatinib hydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib hydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib hydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INC280 hydrochloride; INCB-28060 hydrochloride. CAS No. 1029714-89-3. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13404B. | |
| Dexelvucitabine | Dexelvucitabine, also known as DPC-817; INCB-8721; PSI-5582; YZ-817, DOC-817, is a nucleoside reverse transcriptase inhibitor potentially for the treatment of HIV infection. Group: Inhibitors. Alternative Names: Dexelvucitabine; beta-D-D-4FC; D-D-4FC; DFC; DPC-817; RVT; INCB-8721; PSI-5582; YZ-817; DOC-817. CAS No. 134379-77-4. Molecular formula: C9H10FN3O3. Mole weight: 227.2. Appearance: Solid powder. Purity: >98%. IUPACName: 4-amino-5-fluoro-1-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1H)-one. Canonical SMILES: OC[C@@H]1C=C[C@H] (N2C (N=C (C (F)=C2)N)=O)O1. Catalog: ACM134379774. | |
| Dimesylate | Dimesylate. Group: Biochemicals. Alternative Names: N-[2-[[(3R)-1-[Trans-4-hydroxy-4-(6-methoxy-3-pyridinyl)cyclohexyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-benzamide Methanesulfonate; INCB 3284. Grades: Highly Purified. CAS No. 887401-93-6. Pack Sizes: 5mg. Molecular Formula: C28H37F3N4O10S2, Molecular Weight: 710.74. US Biological Life Sciences. | Worldwide |
| Epacadostat | Epacadostat, also known as INCB024360 or INCB24360, is a potent and selective IDO1 inhibitor with IC50 of 71.8 nM±17.5 nM, with potential immunomodulating and antineoplastic activities. It has been shown to promote T and natural killer-cell growth, to increase IFN-γ production, and to reduce conversion to regulatory T (Treg)-like cells in a coculture system of human allogeneic lymphocytes with either dendritic cells or tumor cells. Synonyms: IDO inhibitor 1; 1,2,5-Oxadiazole-3-carboximidamide, 4-[[2-[(aminosulfonyl)amino]ethyl]amino]-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-, [C(Z)]-; [C(Z)]-4-[[2-[(Aminosulfonyl)amino]ethyl]amino]-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide; ICBN 24360; ICBN-24360; ICBN24360; INCB 024360; INCB024360; INCB-024360. Grades: ≥95%. CAS No. 1204669-58-8. Molecular formula: C11H13BrFN7O4S. Mole weight: 438.23. | |
| Epacadostat | Epacadostat (INCB 024360) is a potent and selective indoleamine 2,3-dioxigenase 1 (IDO1) inhibitor with an IC 50 of 71.8 nM [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB 024360. CAS No. 1204669-58-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g; 2 g. Product ID: HY-15689. | |
| Epacadostat | Epacadostat/ INCB24360 is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1). An investigational drug for cancer in phase 3. Group: Fluorinated apis. Alternative Names: INCB24360. CAS No. 1204669-58-8. Molecular formula: C11H13BrFN7O4S. Mole weight: 438.23. Purity: 0.98. IUPACName: N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide. Catalog: OFC1204669588. | |
| Itacitinib | Itacitinib (INCB039110) is an orally active and selective inhibitor of JAK1 with an IC 50 of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB039110. CAS No. 1334298-90-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-16997. | |
| Itacitinib | Itacitinib is a potent and selective JAK1 inhibitor developed for the treatment of Graft-versus-host disease and non-small cell lung cancer. Synonyms: INCB 039110; 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile. Grades: >98%. CAS No. 1334298-90-6. Molecular formula: C26H23F4N9O. Mole weight: 553.51. | |
| Numidargistat | Numidargistat (CB-1158) is a potent and orally active inhibitor of arginase , with IC 50 s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2 , respectively. Immuno-oncology agent [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CB-1158; INCB01158. CAS No. 2095732-06-0. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg. Product ID: HY-101979. | |
| Parsaclisib | Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ , with an IC 50 of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB050465; IBI-376. CAS No. 1426698-88-5. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109068. | |
| Parsaclisib hydrochloride | Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ , with an IC 50 of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB050465 hydrochloride; IBI-376 hydrochloride. CAS No. 1995889-48-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109068A. | |
| Pemigatinib | Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC 50 s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB054828. CAS No. 1513857-77-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-109099. | |
| Pemigatinib | Pemigatinib is an inhibitor of fibroblast growth factor receptor types 1, 2, and 3 (FGFR1/2/3). Under the brand name Pemazyre, it is used as a medication for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. Synonyms: INCB054828. CAS No. 1513857-77-6. Molecular formula: C24H27F2N5O4. Mole weight: 487.5. | |
| PF-4136309 | PF-4136309 is a potent, selective, and orally bioavailable antagonist of CCR2, a chemokine receptor of the super family of seven-transmembrane G-protein-coupled receptors (GPCRs). Synonyms: (S)-N-(2-(3-((4-hydroxy-4-(5-(pyrimidin-2-yl)pyridin-2-yl)cyclohexyl)amino)pyrrolidin-1-yl)-2-oxoethyl)-3-(trifluoromethyl)benzamide; PF4136309; PF 4136309; PF04136309; PF-04136309; INCB8761; INCB 8761; INCB-8761. CAS No. 1341224-83-6. Molecular formula: C29H31F3N6O3. Mole weight: 568.59. | |
| Povorcitinib | Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB54707. CAS No. 1637677-22-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145588. | |
| Povorcitinib phosphate | Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1) [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB54707 phosphate. CAS No. 1637677-33-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145588A. | |
| Ruxolitinib | Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC 50 s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3 [1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB18424. CAS No. 941678-49-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-50856. | |
| Ruxolitinib | Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy. Group: Inhibitors. Alternative Names: Ruxolitinib; (R)-3-(4-(7H-Pyrrolo[2, 3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; 1H-Pyrazole-1-propanenitrile. beta.-cyclopentyl-4-(7H-pyrrolo[2, 3-d]pyriMidin-4-yl)-, (.beta.R)-; (3R)-3-(4-(7H-pyrrolo[2, 3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; (3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2, 3-d]pyriMidin-4-yl}-1H-pyrazol-1-yl)propanenitrile; INCB018424 (Ruxolitinib);Jakafi. CAS No. 941678-49-5. Molecular formula: C17H18N6. Mole weight: 306.371. Purity: 0.9997. Density: 1.4. Catalog: ACM941678495. | |
| Ruxolitinib | Ruxolitinib is a potent and selective JAK1/2 inhibitor with IC50 values of 3.3 nM and 2.8 nM respectively in cell-free assays, and has > 130-fold selectivity for JAK1/2 versus JAK3. Synonyms: (R)-Ruxolitinib; INCB018424; R-INCB018424; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile. Grades: >98%. CAS No. 941678-49-5. Molecular formula: C17H18N6. Mole weight: 306.37. | |
| Ruxolitinib, Free Base | Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC50's of 2.7 and 4.5nm for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis. Group: Biochemicals. Alternative Names: (b-R)-b-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; INCB018424, INC18424, NCB018424, NCB18424. Grades: Purified. CAS No. 941678-49-5. Pack Sizes: 5mg, 10mg, 25mg, 50mg, 100mg. US Biological Life Sciences. | Worldwide |
| Ruxolitinib phosphate | Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC 50 s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB018424 phosphate. CAS No. 1092939-17-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g. Product ID: HY-50858. | |
| Ruxolitinib phosphate | Ruxolitinib phosphate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Synonyms: INCB018424 phosphate; INCB 018424 phosphate; INCB-018424 phosphate. Grades: >98%. CAS No. 1092939-17-7. Molecular formula: C17H21N6O4P. Mole weight: 404.36. | |
| Ruxolitinib sulfate | Ruxolitinib sulfate (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Synonyms: Ruxolitinib sulfate; 1092939-16-6; INCB018424 sulfate; beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(betaR)-1H-pyrazole-1-propanenitrile, (2Z)-2-butenedioate); SCHEMBL22127335; BCP27733; FT-0770538; 1092939-15-5; A921922; INCB018424 sulfate; INCB 018424 sulfate; INCB-018424 sulfate; 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; sulfuric acid. Grades: >98%. CAS No. 1092939-16-6. Molecular formula: C17H20N6O4S. Mole weight: 404.44. | |
| (S)-Ruxolitinib | Ruxolitinib S enantiomer, the chirality of INCB018424, is a potent and selective small-molecule Janus kinase 1 (JAK1) and JAK2 inhibitor to enter the clinic. It was initially developed to target the constitutive activation of the JAK-STAT pathway. It maintains its anti-JAK activity by competitive inhibition of the ATP-binding catalytic site of the kinase domain. It is well absorbed at above 95%. Synonyms: (S)-INCB018424; S-Ruxolitinib; SRuxolitinib; S Ruxolitinib; INCB-18424. Grades: >98%. CAS No. 941685-37-6. Molecular formula: C17H18N6. Mole weight: 306.37. | |
| Zilurgisertib | Zilurgisertib (INCB-000928; NBU-928) is a selective ALK 2 inhibitor for researching diseases such as cancer. Uses: Scientific research. Group: Signaling pathways. Alternative Names: INCB-000928; NBU-928. CAS No. 2173389-57-4. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145608. | |
Our database is helping our users find suppliers everyday.
